Display options
Cite
Kiiskinen U, Matthaei S, Reaney M, et al. Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study. Clinicoecon Outcomes Res. 2013;5:355-67doi: 10.2147/CEOR.S44060.
Kiiskinen, U., Matthaei, S., Reaney, M., Mathieu, C., Ostenson, C. G., Krarup, T., Theodorakis, M., Kiljański, J., Salaun-Martin, C., Sapin, H., & Guerci, B. (2013). Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study. ClinicoEconomics and outcomes research : CEOR, 5355-67. https://doi.org/10.2147/CEOR.S44060
Kiiskinen, Urpo, et al. "Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study." ClinicoEconomics and outcomes research : CEOR vol. 5 (2013): 355-67. doi: https://doi.org/10.2147/CEOR.S44060
Kiiskinen U, Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Theodorakis M, Kiljański J, Salaun-Martin C, Sapin H, Guerci B. Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study. Clinicoecon Outcomes Res. 2013 Jul 11;5:355-67. doi: 10.2147/CEOR.S44060. Print 2013. PMID: 23874113; PMCID: PMC3713896.
Copy Download .nbib Format: NLM
Share it on

Clinicoecon Outcomes Res. 2013 Jul 11;5:355-67. doi: 10.2147/CEOR.S44060. Print 2013.

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

ClinicoEconomics and outcomes research : CEOR

Urpo Kiiskinen, Stephan Matthaei, Matthew Reaney, Chantal Mathieu, Claes-Göran Ostenson, Thure Krarup, Michael Theodorakis, Jacek Kiljański, Carole Salaun-Martin, Hélène Sapin, Bruno Guerci

Affiliations

  1. Eli Lilly, Helsinki, Finland; , Germany.

PMID: 23874113 PMCID: PMC3713896 DOI: 10.2147/CEOR.S44060

Abstract

PURPOSE: CHOICE (CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy) assessed patterns of exenatide bid and initial insulin therapy usage in clinical practice in six European countries and evaluated outcomes during the study.

METHODS: CHOICE was a 24-month, prospective, noninterventional observational study. Clinical and resource use data were collected at initiation of first injectable therapy (exenatide bid or insulin) and at regular intervals for 24 months. Costs were evaluated from the national health care system perspective at 2009 prices.

RESULTS: A total of 2515 patients were recruited. At the 24-month analysis, significant treatment change had occurred during the study in 42.2% of 1114 eligible patients in the exenatide bid cohort and 36.0% of 1274 eligible patients in the insulin cohort. Improvements in glycemic control were observed over the course of the study in both cohorts (P < 0.001 for both), but mean weight was reduced in the exenatide bid cohort (P < 0.001) and increased in the insulin cohort (P < 0.001) by 24 months. Across all countries, total per patient health care costs for the 24 months post baseline were €3997.9 in the exenatide bid cohort and €3265.5 in the insulin cohort (€1791.9 versus €2465.5 due to costs other than those of injectable therapy). When baseline direct cost and patients' and disease characteristics were controlled for, mean direct costs differed by country (P < 0.0001), irrespective of treatment initiated, and the mean cost difference between treatments varied by country (P < 0.0001).

CONCLUSION: Much of the higher mean cost of exenatide bid, compared with insulin, therapy was compensated for by lower mean costs of other health service utilization. Costs associated with exenatide bid or insulin initiation varied across countries, highlighting the need to avoid generalization of resource use and cost implications of a particular therapy when estimated in specific country settings.

Keywords: exenatide; health care costs; injectable therapy; insulin; resource use; type 2 diabetes mellitus

References

  1. Diabetes Obes Metab. 2012 Jan;14(1):77-82 - PubMed
  2. J Med Econ. 2011;14(1):16-27 - PubMed
  3. Clin Ther. 2007;29 Spec No:1284-92 - PubMed
  4. Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060 - PubMed
  5. Curr Med Res Opin. 2007 Mar;23(3):609-22 - PubMed
  6. Diabetes Ther. 2013 Dec;4(2):285-308 - PubMed
  7. Emerg Med J. 2003 Jan;20(1):54-60 - PubMed
  8. Clin Ther. 2007 Nov;29(11):2333-48 - PubMed
  9. Am J Manag Care. 2010 Jun;16(6):467-71 - PubMed
  10. BMJ. 2012 Jun 12;344:e3974 - PubMed
  11. Clin Ther. 2012 Jun;34(6):1247-1258.e22 - PubMed
  12. Diabetologia. 2007 Feb;50(2):259-67 - PubMed
  13. Appl Health Econ Health Policy. 2009;7(4):245-54 - PubMed
  14. N Engl J Med. 2011 May 5;364(18):1685-7 - PubMed
  15. Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15 - PubMed
  16. Health Technol Assess. 2010 Mar;14(12):1-140 - PubMed
  17. Diabetes Ther. 2012 Nov;3(1):6 - PubMed
  18. Endocrinol Nutr. 2011 Aug-Sep;58(7):331-40 - PubMed
  19. BMJ. 2012 Jun 12;344:e3987 - PubMed
  20. J Med Econ. 2011;14(6):673-80 - PubMed
  21. Diabetes Obes Metab. 2009 Nov;11(11):1068-79 - PubMed
  22. Ann Intern Med. 2005 Oct 18;143(8):559-69 - PubMed
  23. Am J Manag Care. 2010 Jun;16(6):410-1 - PubMed

Publication Types